XML 30 R20.htm IDEA: XBRL DOCUMENT
v3.23.3

Note 14 - Distribution Agreements | 9 Months Ended
--- | ---
Sep. 30, 2023
Notes to Financial Statements |
License, Collaboration, and Distribution Agreements [Text Block] | NOTE 14. DISTRIBUTION AGREEMENTS Transactions under the Company’s major distribution agreements are recognized upon transfer of control of product sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns. Product Sales Discounts and Allowances The following table presents activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration for the nine months ended September 30, 2023 (in thousands):
|  | Product Returns, Discounts for Prompt Payment |  |  | Other Customer Fees |  |  | Rebates |  |  | Total |
Balance at December 31, 2022 |  | $ | 1,673 |  |  | $ | 53 |  |  | $ | 81 |  |  | $ | 1,807 |
Provision related to sales made in current period |  |  | 521 |  |  |  | 104 |  |  |  | 79 |  |  |  | 704 |
Payments and customer credits issued |  |  | (1,194 | ) |  |  | (141 | ) |  |  | (134 | ) |  |  | (1,469 | )
Balance at September 30, 2023 |  | $ | 1,000 |  |  | $ | 16 |  |  | $ | 26 |  |  | $ | 1,042 |
Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. The Company has also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the three months ended September 30, 2023 and 2022, the Company earned $232 thousand and $170 thousand, respectively, in net sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements. During the nine months ended September 30, 2023 and 2022, the Company earned $519 thousand and $113 thousand, respectively, in net sales revenue for its Avenova Spray product from these distribution and partner pharmacy agreements. Under these product distribution arrangements, the Company had a contract liability balance of $0.7 million and $1.6 million as of September 30, 2023 and December 31, 2022, respectively. The contract liability is included in accrued liabilities in the condensed consolidated balance sheets. The Company also recorded a prepayment of $141 thousand for rebates related to these distribution agreements as of September 30, 2023, with no such prepayment recorded as of December 31, 2022, that is recorded in the prepaid expenses and other current assets in the condensed consolidated balance sheets (see Note 4, “Prepaid Expenses and Other Current Assets”). Over-the-Counter Sales of Avenova Spray Avenova Spray is offered for sale direct to U.S. customers primarily on Amazon.com, the Company’s website (Avenova.com) and Walmart.com. During the three and nine months ended September 30, 2023, the revenue generated from over-the-counter Avenova Spray was $1.6 million and $4.5 million, respectively. During the three and nine months ended September 30, 2022, the revenue generated from over-the-counter Avenova Spray was $1.6 million and $5.1 million, respectively. DERMAdoctor Products Distribution Agreements DERMAdoctor products are sold through distribution arrangements with third parties such as Costco and others. During the three and nine months ended September 30, 2023, the Company earned $0.1 million and $0.5 million, respectively, in sales revenue for its DERMAdoctor products from these distribution agreements. During both the three and nine months ended September 30, 2022, the Company earned $0.4 million in sales revenue for its DERMAdoctor products from these distribution agreements. Under these distribution arrangements, the Company had a contract liability balance of $0.3 million and $0.2 million as of September 30, 2023 and December 31, 2022, respectively. The contract liability is included in accrued liabilities in the condensed consolidated balance sheets.

X
- Definition Tabular disclosure of license, collaboration, and distribution agreements. + References No definition available. + Details
Name: | nby_LicenseCollaborationAndDistributionAgreementsTextBlock
Namespace Prefix: | nby_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration